Fit After Baby: Increasing Postpartum Weight Loss in Women at Increased Risk for Cardiometabolic Disease
NCT ID: NCT03215173
Last Updated: 2021-03-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
82 participants
INTERVENTIONAL
2017-09-01
2020-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Healthy4Baby: Preventing Postpartum Weight Retention Among Low-Income, Black Women
NCT01530776
Strategies for Implementing a Postpartum Lifestyle Intervention in WIC Clinics
NCT06116149
Lifestyle Interventions in Overweight and Obese Postpartum Women
NCT03826394
Postpartum Weight Loss for Women at Elevated Cardiovascular Risk
NCT04914819
Cardiovascular Health in Postpartum Women Diagnosed With Excessive Gestational Weight Gain
NCT02142452
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fit After Baby Group
Fit After Baby mobile health lifestyle intervention to increase postpartum weight loss, increase postpartum physical activity, and improve postpartum diet.
Fit After Baby
Mobile application
Text4Baby Control Group
Receive text messages from the free Text4Baby program.
Text4Baby Control Group
Receive free text messages
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fit After Baby
Mobile application
Text4Baby Control Group
Receive free text messages
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Postpartum Body Mass Index (BMI): 26- 45 kg/m2 (≥24 for Asians)
3. Positive history of one or more of the following complications in most recent singleton or twin pregnancy:
1. Gestational diabetes mellitus (by Carpenter-Coustan criteria, IADPSG (International Association of the Diabetes and Pregnancy Study Groups) criteria, or a documented clinical diagnosis). Women with a glucose value \>200 mg/dL after a 50-g glucose challenge test at \>12 weeks gestation will also be included.
2. Preeclampsia (high blood pressure and proteinuria diagnosed after 20 weeks gestation)
3. Gestational hypertension (new hypertension diagnosed after 20 weeks without proteinuria)
4. Pre-term delivery (32-37 weeks)
5. Small for gestational age (\<10th percentile for gestational age)
4. Access to and be willing to use a wi-fi enabled iPhone (5 or higher) or iPod (5 or higher).
5. Capable of providing informed consent
6. Between 4 weeks and 16 weeks after delivery
Exclusion Criteria
2. Personal history of breast cancer or any other type of cancer other than a basal cell skin cancer;
3. Personal history of major chronic illness all to be assessed by the study physician for ability to participate, including:
1. cardiovascular disease (coronary artery disease, congestive heart failure, valvular heart disease, stroke, transient ischemic attack, or intermittent claudication),
2. kidney disease affecting kidney function severe enough to affect participation,
3. liver disease affecting liver function severely enough to affect participation,
4. venous or arterial thromboembolic disease,
5. untreated adrenal insufficiency,
6. depression requiring hospitalization within the past 6 months, or
7. non-pregnancy related illness requiring overnight hospitalization in the past 6 months;
4. Underlying disease/treatment that might interfere with participation in/completion of the study (e.g. significant gastrointestinal conditions, major psychiatric disorders affecting the ability to participate, and others at the discretion of the study clinician);
5. Re-current pregnancy;
6. Diagnosis of diseases associated with glucose metabolism;
7. Current or planned participation in a commercial weight loss program (i.e. Jenny Craig) over the duration of the study;
8. Previous or planned bariatric surgery;
9. Taking certain prescription medications including
1. high dose glucocorticoids,
2. atypical antipsychotics associated with weight gain (such as risperdal (risperidone), clozapine (clozaril), olanzapine (zyprexa), quetiapine (seroquel), etc.) or
3. weight loss medications including prescription (Qsymia, phentermine, topiramate, Belviq, Contrave, Saxenda, Orlistat), or non-prescription (Alli) medications;
10. Taking metformin or other medications known to affect glucose metabolism;
11. Other active medical problems detected by examination or laboratory testing, at the discretion of the physician;
12. Any fasting blood glucose \> 126 mg/dl, any HbA1c at or above 6.5%, or any plasma glucose \>200 mg/dl during the first trimester.
18 Years
45 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Colorado, Denver
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jacinda Nicklas, MD, MPH, MA
Role: PRINCIPAL_INVESTIGATOR
University of Colorado, Denver
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Colorado
Aurora, Colorado, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
17-0045
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.